<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0167112</article-id>
<article-id pub-id-type="publisher-id">PONE-D-16-34889</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Infectious diseases</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial control</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Hematology</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Infectious diseases</subject><subj-group><subject>Bacterial diseases</subject><subj-group><subject>Bacteremia</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject><subj-group><subject>Penicillin</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial control</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject><subj-group><subject>Penicillin</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pulmonology</subject><subj-group><subject>Pneumonia</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Staphylococcus</subject><subj-group><subject>Staphylococcus aureus</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Bacterial pathogens</subject><subj-group><subject>Staphylococcus</subject><subj-group><subject>Staphylococcus aureus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Bacterial pathogens</subject><subj-group><subject>Staphylococcus</subject><subj-group><subject>Staphylococcus aureus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Mathematical and statistical techniques</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Regression analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (mathematics)</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Regression analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Comparable Effectiveness of First Week Treatment with Anti-Staphylococcal Penicillin versus Cephalosporin in Methicillin-Sensitive <italic>Staphylococcus aureus</italic> Bacteremia: A Propensity-Score Adjusted Retrospective Study</article-title>
<alt-title alt-title-type="running-head">Anti-Staphylococcal Penicillin versus Cephalosporin in <italic>S. aureus</italic> Bacteremia: A PS-Adjusted Analysis</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Forsblom</surname>
<given-names>Erik</given-names>
</name>
<xref ref-type="corresp" rid="cor001">*</xref>
<xref ref-type="aff" rid="aff001"/>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Ruotsalainen</surname>
<given-names>Eeva</given-names>
</name>
<xref ref-type="aff" rid="aff001"/>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Järvinen</surname>
<given-names>Asko</given-names>
</name>
<xref ref-type="aff" rid="aff001"/>
</contrib>
</contrib-group>
<aff id="aff001"><addr-line>Division of Infectious Diseases, Inflammation Center, Helsinki University Central Hospital, Finland and University of Helsinki, City of Helsinki, Finland</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Adam</surname>
<given-names>Rodney D</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Aga Khan University Hospital Nairobi, KENYA</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con">
<p><list list-type="simple">
<list-item><p><bold>Conceptualization:</bold> EF ER AJ.</p></list-item>
<list-item><p><bold>Data curation:</bold> EF ER AJ.</p></list-item>
<list-item><p><bold>Formal analysis:</bold> EF ER AJ.</p></list-item>
<list-item><p><bold>Funding acquisition:</bold> EF ER AJ.</p></list-item>
<list-item><p><bold>Investigation:</bold> EF ER AJ.</p></list-item>
<list-item><p><bold>Methodology:</bold> EF ER AJ.</p></list-item>
<list-item><p><bold>Project administration:</bold> AJ.</p></list-item>
<list-item><p><bold>Resources:</bold> EF ER AJ.</p></list-item>
<list-item><p><bold>Software:</bold> EF AJ.</p></list-item>
<list-item><p><bold>Supervision:</bold> AJ.</p></list-item>
<list-item><p><bold>Validation:</bold> EF ER AJ.</p></list-item>
<list-item><p><bold>Visualization:</bold> EF ER AJ.</p></list-item>
<list-item><p><bold>Writing – original draft:</bold> EF ER AJ.</p></list-item>
<list-item><p><bold>Writing – review &amp; editing:</bold> EF ER AJ.</p></list-item></list></p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">erik.forsblom@helsinki.fi</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>29</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>11</volume>
<issue>11</issue>
<elocation-id>e0167112</elocation-id>
<history>
<date date-type="received">
<day>31</day>
<month>8</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>8</day>
<month>11</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-year>2016</copyright-year>
<copyright-holder>Forsblom et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0167112"/>
<abstract>
<p>The objective was to compare the prognostic impact of first week treatment with anti-staphylococcal penicillin (ASP) versus cephalosporin in methicillin-sensitive <italic>Staphylococcus aureus</italic> bacteremia (MS-SAB). Altogether 580 patients were retrospectively followed and categorized according to first week treatment; 84% (488) received ASP (cloxacillin) and 16% (92) cephalosporin (cefuroxime or ceftriaxone). SAB management was optimized with formal bedside infectious disease specialist consultation in 88%, deep infection foci diagnosed in 77% and adjunctive rifampicin therapy given to 61% of patients. The total case fatality in 580 patients was 12% at 28 days and 18% at 90 days. When comparing effectiveness of first week ASP versus cephalosporin treatment there were no significant differences in 28-days (11% vs. 12%, OR; 1.05, 95% CI, 0.53–2.09) or 90-days (17% vs. 21% OR; 1.25, 95% CI, 0.72–2.19) outcome. In univariate analysis no prognostic impact of either first week ASP or cephalosporin treatment was observed for 28-days (OR; 0.96, 95% CI, 0.48–1.90 and OR; 1.05, 95% CI, 0.53–2.09) or 90-days (OR; 0.80, 95% CI, 0.46–1.39 and OR; 1.25, 95% CI, 0.72–2.19) outcome. Propensity-score adjusted Cox proportional regression analysis for first week treatment with cephalosporin demonstrated no significant prognostic impact at 28-days (HR 1.54, 95% CI 0.72–3.23) or 90-days (HR 1.56, 95% CI 0.88–2.86). In conclusion: There is a comparable effectiveness with respect to 28- and 90-days outcome for first week treatment with ASP versus cephalosporin in MS-SAB. The results indicate that the difference in prognostic impact between first week ASP and cephalosporin may be non-significant in patient cohorts with SAB management optimized by infectious disease specialist consultation.</p>
</abstract>
<funding-group>
<funding-statement>The study has been supported by grants from The Medical Society of Finland and the foundations Medicinska Understödsföreningen Liv och Hälsa and Dorothea Olivia, Karl Walter och Jarl Walter Perkléns minne. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="2"/>
<table-count count="4"/>
<page-count count="13"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>Both The Institutional Review Board of Helsinki University Central Hospital and The Ethical Committee of Helsinki University Central Hospital strictly forbid any sharing of clinical patient data. The clinical patient data in this study can under no circumstances be made public. We are by law not allowed to share any of the clinical patient information. The clinical patient data of this study can be stored only within the database of Helsinki University Central Hospital. However, regarding further research (e.g., meta-analyses by other research groups) the data needed to make the final analyses can be shared upon request. Requests for data (e.g., regarding future meta-analyses) will be received by corresponding author Dr. Erik Forsblom (e-mail: <email xlink:type="simple">erik.forsblom@helsinki.fi</email>).</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p><italic>Staphylococcus aureus</italic> is a leading bloodstream pathogen worldwide both in community- and healthcare-associated bacteremia (SAB) [<xref ref-type="bibr" rid="pone.0167112.ref001">1</xref>,<xref ref-type="bibr" rid="pone.0167112.ref002">2</xref>]. The prognosis of SAB is impaired by high age [<xref ref-type="bibr" rid="pone.0167112.ref002">2</xref>–<xref ref-type="bibr" rid="pone.0167112.ref005">5</xref>], hemodynamic instability [<xref ref-type="bibr" rid="pone.0167112.ref002">2</xref>–<xref ref-type="bibr" rid="pone.0167112.ref004">4</xref>] and complications like endocarditis or pneumonia [<xref ref-type="bibr" rid="pone.0167112.ref002">2</xref>–<xref ref-type="bibr" rid="pone.0167112.ref004">4</xref>] whereas deep infection focus identification [<xref ref-type="bibr" rid="pone.0167112.ref004">4</xref>,<xref ref-type="bibr" rid="pone.0167112.ref005">5</xref>] and infectious disease specialist consultation have improved outcome [<xref ref-type="bibr" rid="pone.0167112.ref002">2</xref>,<xref ref-type="bibr" rid="pone.0167112.ref003">3</xref>,<xref ref-type="bibr" rid="pone.0167112.ref005">5</xref>]. Despite advances in SAB management, mortality remains high, ranging from 20%-32% in recent studies [<xref ref-type="bibr" rid="pone.0167112.ref002">2</xref>,<xref ref-type="bibr" rid="pone.0167112.ref003">3</xref>]. Traditionally, anti-staphylococcal penicillin (ASP) have been the first-line choice for methicillin-sensitive <italic>S</italic>. <italic>aureus</italic> (MS-SAB) whereas cephalosporin have been regarded as a secondary alternative [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>–<xref ref-type="bibr" rid="pone.0167112.ref009">9</xref>]. However, there are no randomized studies comparing ASP and cephalosporin in SAB and the recommendation of ASP is based on experimental observations [<xref ref-type="bibr" rid="pone.0167112.ref010">10</xref>,<xref ref-type="bibr" rid="pone.0167112.ref011">11</xref>], clinical experience and retrospective studies only [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>–<xref ref-type="bibr" rid="pone.0167112.ref009">9</xref>]. Furthermore, the results regarding prognostic impact of ASP treatment, as compared to cephalosporin based regimens, have been controversial. In some studies, ASP has resulted in lower mortality when compared to cephalosporin [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>,<xref ref-type="bibr" rid="pone.0167112.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>] but a recent meta-analysis found no difference and another study showed no survival advantage with ASP over first generation cephalosporin cefazolin [<xref ref-type="bibr" rid="pone.0167112.ref009">9</xref>,<xref ref-type="bibr" rid="pone.0167112.ref012">12</xref>].</p>
<p>In real clinical setting treatment of SAB is often commenced with a broad spectrum antibiotic and in countries with low prevalence of methicillin-resistance cephalosporin are widely used as an empiric first-line choice in suspicion of bacteremia [<xref ref-type="bibr" rid="pone.0167112.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>]. Positive blood culture results are usually received by the third day after sampling after-which empirical antimicrobial treatment may be altered into directed therapy [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>,<xref ref-type="bibr" rid="pone.0167112.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>]. Median antimicrobial treatment durations in previous reports have been at least 2 week [<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>,<xref ref-type="bibr" rid="pone.0167112.ref009">9</xref>]. Recent studies have demonstrated that a vast amount of deep infection foci are present already within 3 days [<xref ref-type="bibr" rid="pone.0167112.ref004">4</xref>] and up to 80% of SAB patients present with a deep infection focus [<xref ref-type="bibr" rid="pone.0167112.ref004">4</xref>,<xref ref-type="bibr" rid="pone.0167112.ref005">5</xref>,<xref ref-type="bibr" rid="pone.0167112.ref013">13</xref>]. Furthermore, meticulous deep infection focus localization and infectious disease specialist consultations are known to improved SAB prognosis [<xref ref-type="bibr" rid="pone.0167112.ref002">2</xref>,<xref ref-type="bibr" rid="pone.0167112.ref004">4</xref>,<xref ref-type="bibr" rid="pone.0167112.ref005">5</xref>,<xref ref-type="bibr" rid="pone.0167112.ref013">13</xref>]. Previous studies comparing ASP and cephalosporin in SAB have, however, not included these prognostic factors in their analyses. Moreover, the prognostic impact of continued and prolonged empiric cephalosporin treatment, as compared to targeted ASP treatment during the initial week of MS-SAB has to the best of our knowledge not been evaluated previously.</p>
<p>The objective of the present study was to apply propensity-score adjusted Cox proportional regression analysis to evaluate the effectiveness of first week treatment with ASP versus continued empiric cephalosporin. The study was performed in an MS-SAB patient cohort where the vast majority of patients received infectious disease specialist consultation guided SAB management and most patients had deep infection foci diagnosed.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="sec003">
<title>Ethics statement</title>
<p>The trial was approved by The institutional review board of Helsinki University Central Hospital and The Ethical committee of Helsinki University Central Hospital. A written informed consent was provided by each patient.</p>
</sec>
<sec id="sec004">
<title>Patients and data collection</title>
<p>Adult patients with at least one positive blood culture for methicillin-sensitive <italic>S</italic>. <italic>aureus</italic> were identified. The patient cohort was assembled from two time-periods. Most SAB patients came from an earlier prospective multicenter study including all five university and seven central hospitals in Finland during January 2000 to August 2002 [<xref ref-type="bibr" rid="pone.0167112.ref004">4</xref>]. This cohort was further extended with all SAB cases identified retrospectively who were not included into the prospective study between years 2000 to 2002 and all SAB patients between years 2006 to 2007 from Helsinki University Central Hospital [<xref ref-type="bibr" rid="pone.0167112.ref005">5</xref>,<xref ref-type="bibr" rid="pone.0167112.ref014">14</xref>]. Two time-periods were viewed as mandatory in order to be able to exclude any unknown temporary differences in personnel or treatment practices or other factors difficult to control for. Moreover, patient data come from both written hospital archives (the earlier time-period) and electronic archives (the later time-period) and the inclusion of two time-periods enabled exclusion of differences in patient data storage patterns. We recorded the following data; age, gender, underlying diseases, acquisition of bacteremia, severe sepsis, intensive care unit (ICU) treatment and length and administration route of antibiotic therapy. Infectious diseases specialist consultations were documented. No cases of methicillin-resistant <italic>S</italic>. <italic>aureus</italic> were accepted. Exclusion criteria were: age &lt; 18 years, pregnancy, breastfeeding, imprisonment, epilepsy, bacteremia 28 days prior to the study and poly-microbial bacteremia. Furthermore, patients with first week antibiotic treatment other than ASP or cephalosporin were excluded. Patients were followed for 90 days and primary outcome was mortality at 28- and 90 days.</p>
</sec>
<sec id="sec005">
<title>Definitions</title>
<p>Infectious disease specialist consultations within 7 days of positive blood cultures were recorded and categorized into formal bedside consultation or informal telephone consultation [<xref ref-type="bibr" rid="pone.0167112.ref005">5</xref>]. Healthcare-associated SAB was defined as bacteremia with the first positive blood culture for <italic>S</italic>. <italic>aureus</italic> obtained ≥ 48 hours after hospital admission or when the patient had remained in a long-term care facility or undergone hemodialysis within the preceding two months. McCabe’s criteria were applied to categorize underlying diseases [<xref ref-type="bibr" rid="pone.0167112.ref015">15</xref>]. Severe sepsis was classified as sepsis in combination with hypotension, hypo-perfusion, or organ failure [<xref ref-type="bibr" rid="pone.0167112.ref016">16</xref>]. Infection foci diagnosis was based on bacteriological, pathological or radiological findings or clinical suspicion only.</p>
</sec>
<sec id="sec006">
<title>Antibiotic therapy</title>
<p>The standard antibiotic therapy was cloxacillin, cefuroxime or ceftriaxone. First week antibiotic treatment was defined as a non-delayed onset of cloxacillin, or a continuation of empiric cefuroxime or ceftriaxone, without any interruption for at least 7 days after positive blood cultures. Length of antibiotic therapy was considered proper when administered intravenously for at least 28 days for a deep infection focus and 14 days in the absence of any deep infection. Fluoroquinolone, aminoglycoside and rifampicin served as additional antibiotic therapy. More detailed information on dosages and administration routes have been provided earlier [<xref ref-type="bibr" rid="pone.0167112.ref013">13</xref>,<xref ref-type="bibr" rid="pone.0167112.ref014">14</xref>].</p>
</sec>
<sec id="sec007">
<title>Statistical analysis</title>
<p>All values are provided as numbers and percentages unless otherwise specified. Pearson´s X<sup>2</sup> test was applied to compare categorical variables. Odds ratios (OR) and hazard ratios (HR) with 95% confidence intervals (CI) were calculated. Univariate factors with p ≤ 0.1 were accepted for multivariate analysis. Propensity-score was calculated by logistic regression for the assignment of either ASP or cephalosporin as definitive first week antimicrobial therapy. Variables interpreted as relevant for this assignment were; gender, age &gt; 60, healthy-nonfatal disease classification, healthcare-associated SAB, intensive care unit treatment, endocarditis and pneumonia. Next, a propensity-score adjusted Cox proportional regression model analysis was performed to estimate prognostic parameters of 28- and 90-days outcome. Kaplan-Meier interpretation with log-rank estimation was used to graphically demonstrate mortality differences. All tests were two-tailed and p&lt;0.05 was considered as significant. Analyses were done using SPSS version 12.0 (SPSS Inc., Chicago, IL, USA).</p>
</sec>
</sec>
<sec id="sec008" sec-type="results">
<title>Results</title>
<sec id="sec009">
<title>Patient characteristics</title>
<p>Altogether 617 SAB patients were identified. Exclusion criteria were accounted for and patients receiving antibiotic treatment other than ASP or cephalosporin (carbapenemes, clindamycin, vancomycin or piperasillin-tazobactam) were excluded (n = 37). In total 580 patients received either ASP or cephalosporin during the first week (<xref ref-type="fig" rid="pone.0167112.g001">Fig 1</xref>). Patients came from two time-periods; the earlier time-period (n = 467) and the later time-period (n = 113). The median time between blood culture collection and reporting of <italic>S</italic>. <italic>aureus–</italic>positive finding was three days. An intravenous antibiotic treatment effective in vitro against the <italic>S</italic>. <italic>aureus</italic> blood isolate was provided to each patient from the day of positive blood culture. Four hundred and eighty-eight (84%) patients received cloxacillin and 92 (16%) patients were treated with either cefuroxime (75, 82%) or ceftriaxone (17, 18%). No significant difference regarding gender, age, SAB acquisition, or previous hospitalizations was observed between the two groups (<xref ref-type="table" rid="pone.0167112.t001">Table 1</xref>). Patients receiving ASP, as compared to patients treated with cephalosporin, had higher McCabe´s healthy—nonfatal classification (74% vs. 57%, p &lt; 0.01) (<xref ref-type="table" rid="pone.0167112.t001">Table 1</xref>). No difference with respect to severity of illness at blood culture collection time point was observed between the two groups (<xref ref-type="table" rid="pone.0167112.t001">Table 1</xref>). Regarding additional antibiotic treatment there was no significant differences observed between the groups. Altogether 288 (50%) received fluoroquinolone, 99 (17%) had aminoglycoside whereas rifampicin was provided to 353 (61%) and only 8 (1.4%) of patients were treated with additional vancomycin therapy (<xref ref-type="table" rid="pone.0167112.t001">Table 1</xref>).</p>
<fig id="pone.0167112.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0167112.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Study profile.</title>
<p>Originally 617 patients with methicillin-sensitive <italic>Staphylococcus aureus</italic> bacteraemia (SAB) were identified. Patients with methicillin-resistant SAB were not included in the study. Patients were divided according to anti-staphylococcal penicillin (cloxacillin) or cephalosporin (cefuroxime or ceftriaxone) therapy during the 1<sup>st</sup> week. <sup>1</sup> Carbapenemes, Clindamycin, Vancomycin or Piperasillin-Tazobactam <sup>2</sup> Cefuroxime or ceftriaxone <sup>3</sup> Cloxacillin</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0167112.g001" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0167112.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0167112.t001</object-id>
<label>Table 1</label> <caption><title>Patient characteristics, severity of illness, treatment management and outcome of 580 patients with methicillin-sensitive <italic>Staphylococcus aureus</italic> bacteraemia (SAB).</title> <p>Patients are categorised according to first week antimicrobial therapy into anti-staphylococcal penicillin or cephalosporin. Values are n (%). NS = non-significant.</p></caption>
<alternatives>
<graphic id="pone.0167112.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0167112.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center"/>
<th align="center" colspan="2">Antibiotic therapy</th>
<th align="center" colspan="2">Cephalosporin vs. Anti-staphylococcal penicillin</th>
</tr>
<tr>
<th align="center">Variables</th>
<th align="center">Anti-staphylococcal penicillin <xref ref-type="table-fn" rid="t001fn001"><sup>1</sup></xref> n = 488 (84)</th>
<th align="center">Cephalosporin <xref ref-type="table-fn" rid="t001fn002"><sup>2</sup></xref> n = 92 (16)</th>
<th align="center">OR (95% CI)</th>
<th align="center">p- value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="justify"><bold>Patient characteristics</bold></td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="justify">Male sex</td>
<td align="center">302 (62)</td>
<td align="center">58 (63)</td>
<td align="center">1.05 (0.66–1.66)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="justify">Age &gt; 60 years</td>
<td align="center">238 (49)</td>
<td align="center">35 (38)</td>
<td align="center">0.65 (0.41–1.02)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="justify">Healthcare-associated SAB</td>
<td align="center">258 (53)</td>
<td align="center">49 (53)</td>
<td align="center">1.02 (0.65–1.59)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="justify">Healthy-nonfatal disease <xref ref-type="table-fn" rid="t001fn003"><sup><bold>A</bold></sup></xref></td>
<td align="center">362 (74)</td>
<td align="center">52 (57)</td>
<td align="center">0.45 (0.29–0.72)</td>
<td align="center">&lt;0.01</td>
</tr>
<tr>
<td align="justify">Previous hospitalization <xref ref-type="table-fn" rid="t001fn004"><sup><bold>B</bold></sup></xref></td>
<td align="center">259 (53)</td>
<td align="center">55 (60)</td>
<td align="center">1.31 (0.84–2.07)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="justify">Intensive care unit <xref ref-type="table-fn" rid="t001fn005"><sup><bold>C</bold></sup></xref></td>
<td align="center">89 (18)</td>
<td align="center">20 (22)</td>
<td align="center">1.25 (0.72–2.15)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="justify">Deep infection focus</td>
<td align="center">383 (78)</td>
<td align="center">64 (70)</td>
<td align="center">0.63 (0.38–1.03)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="justify">Endocarditis</td>
<td align="center">81 (17)</td>
<td align="center">9 (10)</td>
<td align="center">0.55 (0.26–1.13)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="justify">Pneumonia</td>
<td align="center">181 (37)</td>
<td align="center">37 (40)</td>
<td align="center">1.14 (0.72–1.79)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="justify">Vancomycin</td>
<td align="center">8 (2)</td>
<td align="center">0</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td align="justify">Fluoroquinolone</td>
<td align="center">245 (50)</td>
<td align="center">43 (47)</td>
<td align="center">0.87 (0.56–1.36)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="justify">Aminoglycoside</td>
<td align="center">79 (16)</td>
<td align="center">20 (22)</td>
<td align="center">1.44 (0.83–2.49)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="justify">Rifampicin</td>
<td align="center">301 (62)</td>
<td align="center">52 (57)</td>
<td align="center">0.81 (0.52–1.27)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="justify"><bold>Mortality at 28 days</bold></td>
<td align="center">56 (11)</td>
<td align="center">11 (12)</td>
<td align="center">1.05 (0.53–2.09)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="justify"><bold>Mortality at 90 days</bold></td>
<td align="center">84 (17)</td>
<td align="center">19 (21)</td>
<td align="center">1.25 (0.72–2.19)</td>
<td align="center">NS</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p><sup>1</sup> Cloxacillin</p></fn>
<fn id="t001fn002"><p><sup>2</sup> Cefuroxime or ceftriaxone</p></fn>
<fn id="t001fn003"><p><sup>A</sup> Classification according to McCabe and Jackson [<xref ref-type="bibr" rid="pone.0167112.ref015">15</xref>]</p></fn>
<fn id="t001fn004"><p><sup>B</sup> Within 2 months prior to blood culture collection</p></fn>
<fn id="t001fn005"><p><sup>C</sup> Severity of illness at blood culture collection time point</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec010">
<title>Deep infection foci</title>
<p>Altogether 447 (77%) of patients had at least one deep infection focus diagnosed (<xref ref-type="table" rid="pone.0167112.t001">Table 1</xref>). There were no differences in patients receiving ASP or cephalosporin during the first week with respect to occurrence of deep infection foci, endocarditis or pneumonia (<xref ref-type="table" rid="pone.0167112.t001">Table 1</xref>).</p>
</sec>
<sec id="sec011">
<title>Infectious disease specialist consultation</title>
<p>Infectious disease specialist consultation guided SAB management was provided to almost all patients 565 (97%) whereas 15 (3%) were managed without any consultation. The consultations were mostly formal bedside 511 (88%) whereas 54 (9%) had informal telephone consultations (<xref ref-type="table" rid="pone.0167112.t002">Table 2</xref>).</p>
<table-wrap id="pone.0167112.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0167112.t002</object-id>
<label>Table 2</label> <caption><title>Univariate analysis of prognostic factors for 28- and 90-days mortality in 580 patients with methicillin-sensitive <italic>Staphylococcus aureus</italic> bacteremia.</title> <p>Values are expressed as N (%). NS = non-significant.</p></caption>
<alternatives>
<graphic id="pone.0167112.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0167112.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"/>
<th align="center" colspan="4">28-days</th>
<th align="center" colspan="4">90-days</th>
</tr>
<tr>
<th align="center">Variables</th>
<th align="center">Died 67 (12)</th>
<th align="center">Survived 513 (88)</th>
<th align="center">OR (95% CI)</th>
<th align="center">p- value</th>
<th align="center">Died 103 (18)</th>
<th align="center">Survived 477 (82)</th>
<th align="center">OR (95% CI)</th>
<th align="center">p- value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><bold>Patient characteristics</bold></td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left">Male sex</td>
<td align="center">43 (64)</td>
<td align="center">317 (62)</td>
<td align="center">1.11 (0.65–1.88)</td>
<td align="center">NS</td>
<td align="center">62 (60)</td>
<td align="center">298 (62)</td>
<td align="center">0.91 (0.59–1.41)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="left">Age &gt; 60 years</td>
<td align="center">52 (78)</td>
<td align="center">221 (43)</td>
<td align="center">4.58 (2.51–8.35)</td>
<td align="center">&lt; 0.001</td>
<td align="center">73 (71)</td>
<td align="center">200 (42)</td>
<td align="center">3.37 (2.12–5.35)</td>
<td align="center">&lt; 0.001</td>
</tr>
<tr>
<td align="left">Healthcare-associated SAB</td>
<td align="center">36 (54)</td>
<td align="center">271 (53)</td>
<td align="center">1.04 (0.62–1.73)</td>
<td align="center">NS</td>
<td align="center">65 (63)</td>
<td align="center">242 (51)</td>
<td align="center">1.66 (1.07–2.58)</td>
<td align="center">&lt; 0.05</td>
</tr>
<tr>
<td align="left">Healthy—nonfatal disease <xref ref-type="table-fn" rid="t002fn001"><sup><bold>A</bold></sup></xref></td>
<td align="center">28 (42)</td>
<td align="center">386 (75)</td>
<td align="center">0.24 (0.14–0.40)</td>
<td align="center">&lt; 0.001</td>
<td align="center">38 (37)</td>
<td align="center">376 (79)</td>
<td align="center">0.16 (0.10–0.25)</td>
<td align="center">&lt; 0.001</td>
</tr>
<tr>
<td align="left">Previous hospitalization <xref ref-type="table-fn" rid="t002fn002"><sup><bold>B</bold></sup></xref></td>
<td align="center">36 (54)</td>
<td align="center">278 (54)</td>
<td align="center">0.98 (0.59–1.64)</td>
<td align="center">NS</td>
<td align="center">64 (62)</td>
<td align="center">250 (52)</td>
<td align="center">1.49 (0.96–2.31)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="left">Intensive care unit <xref ref-type="table-fn" rid="t002fn003"><sup><bold>C</bold></sup></xref></td>
<td align="center">23 (34)</td>
<td align="center">86 (17)</td>
<td align="center">2.59 (1.49–4.52)</td>
<td align="center">&lt; 0.01</td>
<td align="center">29 (28)</td>
<td align="center">80 (17)</td>
<td align="center">1.95 (1.19–3.18)</td>
<td align="center">&lt; 0.01</td>
</tr>
<tr>
<td align="left">Endocarditis</td>
<td align="center">19 (28)</td>
<td align="center">71 (14)</td>
<td align="center">2.46 (1.37–4.43)</td>
<td align="center">&lt; 0.01</td>
<td align="center">26 (25)</td>
<td align="center">64 (13)</td>
<td align="center">2.18 (1.30–3.65)</td>
<td align="center">&lt; 0.01</td>
</tr>
<tr>
<td align="left">Pneumonia</td>
<td align="center">41 (61)</td>
<td align="center">177 (35)</td>
<td align="center">2.99 (1.77–5.06)</td>
<td align="center">&lt; 0.001</td>
<td align="center">63 (61)</td>
<td align="center">155 (32)</td>
<td align="center">3.27 (2.11–5.08)</td>
<td align="center">&lt; 0.001</td>
</tr>
<tr>
<td align="left">Cephalosporin <xref ref-type="table-fn" rid="t002fn004"><sup><bold>D</bold></sup></xref></td>
<td align="center">11 (16)</td>
<td align="center">81 (16)</td>
<td align="center">1.05 (0.53–2.09)</td>
<td align="center">NS</td>
<td align="center">19 (18)</td>
<td align="center">73 (15)</td>
<td align="center">1.25 (0.72–2.19)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="left">Anti-staphylococcal penicillin <xref ref-type="table-fn" rid="t002fn005"><sup><bold>E</bold></sup></xref></td>
<td align="center">56 (84)</td>
<td align="center">432 (84)</td>
<td align="center">0.96 (0.48–1.90)</td>
<td align="center">NS</td>
<td align="center">84 (82)</td>
<td align="center">404 (85)</td>
<td align="center">0.80 (0.46–1.39)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="left">Rifampicin therapy</td>
<td align="center">14 (21)</td>
<td align="center">238 (46)</td>
<td align="center">0.31 (0.17–0.56)</td>
<td align="center">&lt; 0.001</td>
<td align="center">30 (29)</td>
<td align="center">252 (53)</td>
<td align="center">0.37 (0.23–0.58)</td>
<td align="center">&lt; 0.01</td>
</tr>
<tr>
<td align="left">Fluoroquinolone</td>
<td align="center">31 (46)</td>
<td align="center">257 (50)</td>
<td align="center">0.86 (0.52–1.43)</td>
<td align="center">NS</td>
<td align="center">48 (47)</td>
<td align="center">240 (50)</td>
<td align="center">0.86 (0.56–1.32)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="left">Aminoglycoside</td>
<td align="center">13 (19)</td>
<td align="center">86 (17)</td>
<td align="center">1.19 (0.63–2.29)</td>
<td align="center">NS</td>
<td align="center">20 (19)</td>
<td align="center">79 (17)</td>
<td align="center">1.21 (0.70–2.09)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="left">Formal IDSC <xref ref-type="table-fn" rid="t002fn006"><sup><bold>F</bold></sup></xref></td>
<td align="center">58 (87)</td>
<td align="center">453 (88)</td>
<td align="center">0.85 (0.40–1.81)</td>
<td align="center">NS</td>
<td align="center">82 (80)</td>
<td align="center">429 (90)</td>
<td align="center">0.44 (0.25–0.77)</td>
<td align="center">&lt; 0.01</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p><sup>A</sup> Classification according to McCabe [<xref ref-type="bibr" rid="pone.0167112.ref015">15</xref>]</p></fn>
<fn id="t002fn002"><p><sup>B</sup> Within 2 months prior to blood culture collection</p></fn>
<fn id="t002fn003"><p><sup>C</sup> At positive blood culture time point</p></fn>
<fn id="t002fn004"><p><sup>D</sup> Cephalosporin i.e. Cefuroxime or ceftriaxone</p></fn>
<fn id="t002fn005"><p><sup>E</sup> Anti-staphylococcal penicillin i.e. cloxacillin</p></fn>
<fn id="t002fn006"><p><sup>F</sup> Formal bedside infectious disease specialist consultation</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec012">
<title>Mortality</title>
<p>The total case fatality in 580 patients was 12% at 28 days and 18% at 90 days. There was no difference in mortality between first week ASP and cephalosporin treatments at 28 days (11% vs. 12%, OR; 1.05) or at 90 days (17% vs. 21%, OR; 1.25) (Tables <xref ref-type="table" rid="pone.0167112.t001">1</xref> and <xref ref-type="table" rid="pone.0167112.t002">2</xref>, <xref ref-type="fig" rid="pone.0167112.g002">Fig 2</xref>).</p>
<fig id="pone.0167112.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0167112.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Kaplan-Meier interpretation of 90 days outcome in 580 methicillin-sensitive <italic>Staphylococcus aureus</italic> bacteremia patients receiving either anti-staphylococcal penicillin (ASP, cloxacillin) (n = 488) or cephalosporin (cefuroxime or ceftriaxone) (n = 92) as first week antibiotic treatment after positive blood cultures.</title>
<p>Log-rank non-significant.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0167112.g002" xlink:type="simple"/>
</fig>
<p>In univariate analysis; parameters with 28-days prognostic impact were: age &gt; 60 (OR; 4.58, p &lt; 0.001), healthy–nonfatal underlying disease (OR; 0.24, p &lt; 0.001), intensive care unit (OR; 2.59, p &lt; 0.01), endocarditis (OR; 2.46, p &lt; 0.01), pneumonia (OR; 2.99, p &lt; 0.001) and rifampicin therapy (OR; 0.31, p &lt;0.001) whereas parameters for 90-days prognostic impact were very similar to those of 28-days with the additional parameters of healthcare-associated bacteremia (OR; 1.66, p &lt; 0.05) and formal bedside infectious disease consultation (OR; 0.44, p &lt; 0.01) (<xref ref-type="table" rid="pone.0167112.t002">Table 2</xref>). At both 28- and 90-days neither ASP (OR; 0.96, 95% CI, 0.48–1.90 and OR; 0.80, 95% CI, 0.46–1.39) nor cephalosporin treatment (OR; 1.05, 95% CI, 0.53–2.09 and OR; 1.25, 95% CI, 0.72–2.19) had any prognostic impact (<xref ref-type="table" rid="pone.0167112.t002">Table 2</xref>).</p>
<p>A Kaplan-Meier interpretation of the differences in outcome between first weeks ASP versus cephalosporin treatment produced a non-significant log-rank comparison (<xref ref-type="fig" rid="pone.0167112.g002">Fig 2</xref>).</p>
<p>Propensity-score adjusted Cox proportional regression analysis for first week treatment with cephalosporin demonstrated no significant prognostic impact at 28-days (HR 1.54; 95% CI 0.72–3.23) or at 90-days (HR; 1.56, 95% CI 0.88–2.86) (Tables <xref ref-type="table" rid="pone.0167112.t003">3</xref> and <xref ref-type="table" rid="pone.0167112.t004">4</xref>). Parameters with prognostic impact in propensity-score adjusted Cox proportional regression analysis for 28-days outcome were intensive care unit treatment (HR; 2.60, p &lt; 0.01), pneumonia (HR; 2.29, p &lt; 0.05) and additional therapy with rifampicin (HR; 0.24, p &lt; 0.01), whereas parameters for 90-days outcome were; age &gt; 60 years (HR; 5.15, p &lt; 0.01), endocarditis (HR; 4.74, p &lt; 0.01), pneumonia (HR; 2.18, p &lt; 0.01), formal bedside infectious disease specialist consultation (HR; 0.39, p &lt; 0.05) and additional therapy with rifampicin (HR; 0.34, p &lt; 0.01).</p>
<table-wrap id="pone.0167112.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0167112.t003</object-id>
<label>Table 3</label> <caption><title>Propensity-score adjusted Cox proportional regression analysis for 28-days mortality among 580 patients with methicillin-sensitive <italic>Staphylococcus</italic> aureus bacteremia receiving either anti-staphylococcal penicillin (n = 92) or cephalosporin (n = 488) as first week antimicrobial treatment.</title></caption>
<alternatives>
<graphic id="pone.0167112.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0167112.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"/>
<th align="center">PS-adjusted multivariate HR (95% CI)</th>
<th align="center">p- value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Anti-staphylococcal penicillin <xref ref-type="table-fn" rid="t003fn001"><sup><bold>1</bold></sup></xref></td>
<td align="center">1.0</td>
<td align="center">---</td>
</tr>
<tr>
<td align="left">Cephalosporin <xref ref-type="table-fn" rid="t003fn002"><sup><bold>2</bold></sup></xref></td>
<td align="center">1.54 (0.72–3.23)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="left">Male sex</td>
<td align="center">1.26 (0.72–2.21)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="left">Age &gt; 60 years</td>
<td align="center">3.46 (0.83–14.4)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="left">Healthy-nonfatal disease <xref ref-type="table-fn" rid="t003fn003"><sup><bold>A</bold></sup></xref></td>
<td align="center">0.30 (0.05–1.89)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="left">Healthcare-associated bacteremia</td>
<td align="center">0.65 (0.34–1.24)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="left">Intensive care unit <xref ref-type="table-fn" rid="t003fn004"><sup><bold>B</bold></sup></xref></td>
<td align="center">2.60 (1.34–5.03)</td>
<td align="center">&lt; 0.01</td>
</tr>
<tr>
<td align="left">Endocarditis</td>
<td align="center">2.26 (0.65–7.88)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="left">Pneumonia</td>
<td align="center">2.29 (1.31–4.01)</td>
<td align="center">&lt; 0.05</td>
</tr>
<tr>
<td align="left">Formal IDSC <xref ref-type="table-fn" rid="t003fn005"><sup><bold>C</bold></sup></xref></td>
<td align="center">1.03 (0.24–4.50)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="left">Rifampicin therapy <xref ref-type="table-fn" rid="t003fn006"><sup><bold>D</bold></sup></xref></td>
<td align="center">0.24 (0.13–0.49)</td>
<td align="center">&lt; 0.01</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p><sup>1</sup> Cloxacillin</p></fn>
<fn id="t003fn002"><p><sup>2</sup> Cefuroxime or ceftriaxone</p></fn>
<fn id="t003fn003"><p><sup>A</sup> Classification according to McCabe and Jackson [<xref ref-type="bibr" rid="pone.0167112.ref015">15</xref>]</p></fn>
<fn id="t003fn004"><p><sup>B</sup> At blood culture collection time-point</p></fn>
<fn id="t003fn005"><p><sup>C</sup> Infectious disease specialist consultation</p></fn>
<fn id="t003fn006"><p><sup>D</sup> Additional antibiotic therapy</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="pone.0167112.t004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0167112.t004</object-id>
<label>Table 4</label> <caption><title>Propensity-score adjusted Cox proportional regression analysis for 90-day mortality among 580 patients with methicillin-sensitive <italic>Staphylococcus</italic> aureus bacteremia receiving either anti-staphylococcal penicillin (n = 92) or cephalosporin (n = 488) as first week antimicrobial treatment.</title></caption>
<alternatives>
<graphic id="pone.0167112.t004g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0167112.t004" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"/>
<th align="center">PS-adjusted multivariate HR (95% CI)</th>
<th align="center">P- value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Anti-staphylococcal penicillin <xref ref-type="table-fn" rid="t004fn001"><sup><bold>1</bold></sup></xref></td>
<td align="center">1.0</td>
<td align="center">---</td>
</tr>
<tr>
<td align="left">Cephalosporin <xref ref-type="table-fn" rid="t004fn002"><sup><bold>2</bold></sup></xref></td>
<td align="center">1.56 (0.88–2.86)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="left">Male sex</td>
<td align="center">1.15 (9.74–1.78)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="left">Age &gt; 60 years</td>
<td align="center">5.15 (1.77–15.0)</td>
<td align="center">&lt; 0.01</td>
</tr>
<tr>
<td align="left">Healthy-nonfatal disease <xref ref-type="table-fn" rid="t004fn003"><sup><bold>A</bold></sup></xref></td>
<td align="center">0.75 (0.20–2.81)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="left">Healthcare-associated bacteremia</td>
<td align="center">1.29 (0.78–2.13)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="left">Intensive care unit <xref ref-type="table-fn" rid="t004fn004"><sup><bold>B</bold></sup></xref></td>
<td align="center">1.35 (0.79–2.31)</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="left">Endocarditis</td>
<td align="center">4.74 (1.94–11.6)</td>
<td align="center">&lt; 0.01</td>
</tr>
<tr>
<td align="left">Pneumonia</td>
<td align="center">2.18 (1.39–3.42)</td>
<td align="center">&lt; 0.01</td>
</tr>
<tr>
<td align="left">Formal IDSC <xref ref-type="table-fn" rid="t004fn005"><sup><bold>C</bold></sup></xref></td>
<td align="center">0.39 (0.16–0.99)</td>
<td align="center">&lt; 0.05</td>
</tr>
<tr>
<td align="left">Rifampicin therapy <xref ref-type="table-fn" rid="t004fn006"><sup><bold>D</bold></sup></xref></td>
<td align="center">0.34 (0.22–0.53)</td>
<td align="center">&lt; 0.01</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t004fn001"><p><sup>1</sup> Cloxacillin</p></fn>
<fn id="t004fn002"><p><sup>2</sup> Cefuroxime or ceftriaxone</p></fn>
<fn id="t004fn003"><p><sup>A</sup> Classification according to McCabe and Jackson [<xref ref-type="bibr" rid="pone.0167112.ref015">15</xref>]</p></fn>
<fn id="t004fn004"><p><sup>B</sup> At blood culture collection time-point</p></fn>
<fn id="t004fn005"><p><sup>C</sup> Infectious disease specialist consultation</p></fn>
<fn id="t004fn006"><p><sup>D</sup> Additional antibiotic therapy</p></fn>
</table-wrap-foot>
</table-wrap>
<p>The patient cohort came from two separate time-periods. This raises the question whether changes in clinical practice over the years have favored one or the other treatment group. As a further analysis the propensity-score adjusted Cox proportional regression analysis was performed separately for the larger patient subgroup from the earlier time-period. However, the results remained similar to those of Tables <xref ref-type="table" rid="pone.0167112.t003">3</xref> and <xref ref-type="table" rid="pone.0167112.t004">4</xref> with no significant prognostic impact for first week treatment with cephalosporin at 28-days (HR; 1.91, 95% CI 0.45–6.13) and at 90-days (HR; 1.85, 95% CI 0.74–4.65).</p>
<p>The cephalosporin group contained both cefuroxime and ceftriaxone i.e. regimens from two different cephalosporin generations. As a further investigation the main analyses with propensity-score adjusted Cox proportional regression analysis were re-performed by excluding ceftriaxone and comparing only first week treatment with ASP versus cefuroxime. However, the results did not deviate from those of Tables <xref ref-type="table" rid="pone.0167112.t003">3</xref> and <xref ref-type="table" rid="pone.0167112.t004">4</xref> with no significant prognostic impact for first week treatment with cefuroxime at 28-days (HR; 1.78, 95% CI 0.77–4.12) or at 90-days (HR; 1.71, 95% CI 0.90–3.26).</p>
<p>To further evaluate the stability of the main results, patients were categorized in turn according to age or underlying conditions, i.e. two major factors that may have strong influence on outcome, and the propensity-score adjusted Cox proportional regression analysis for 90-days prognostic parameters re-performed. However, when including only patients aged &lt; 60 years or aged &gt; 60 years the 90-days prognostic impact for first week treatment with cephalosporin was non-significant (HR; 2.70, 95% CI 0.85–6.47 and HR; 1.10, 95% CI 0.52–2.35, respectively). Further, when including only patients with McCabe´s healthy-nonfatal or McCabe´s ultimately-rapidly fatal classification the 90-days prognostic impact for first week treatment with cephalosporin was non-significant as well (HR; 0.79, 95% CI 0.26–2.37 and HR; 1.64, 95% CI 0.79–4.35, respectively).</p>
</sec>
</sec>
<sec id="sec013" sec-type="conclusions">
<title>Discussion</title>
<p>The main finding of the present study was a comparable effectiveness with respect to 28- and 90-days outcome for first week treatment with ASP versus cephalosporin in MS-SAB. The results were achieved by propensity-score adjusted Cox proportional regression analysis and the observations remained after re-performing the analysis by categorization of the patient cohort according to data collection time-period, age and underlying conditions.</p>
<p>Several retrospective studies [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>,<xref ref-type="bibr" rid="pone.0167112.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>,<xref ref-type="bibr" rid="pone.0167112.ref009">9</xref>,<xref ref-type="bibr" rid="pone.0167112.ref012">12</xref>,<xref ref-type="bibr" rid="pone.0167112.ref017">17</xref>] have compared the prognostic impact of ASP, mostly cloxacillin, dicloxacillin or oxacillin [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>,<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>,<xref ref-type="bibr" rid="pone.0167112.ref017">17</xref>], and cephalosporin, mostly cefuroxime [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>–<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>]. The patient cohorts have included MS-SAB [<xref ref-type="bibr" rid="pone.0167112.ref007">7</xref>–<xref ref-type="bibr" rid="pone.0167112.ref009">9</xref>,<xref ref-type="bibr" rid="pone.0167112.ref012">12</xref>,<xref ref-type="bibr" rid="pone.0167112.ref017">17</xref>] whereas one study included penicillin-sensitive SAB (PS-SAB) patients only [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>]. These studies demonstrated lower [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>–<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>] or indifferent [<xref ref-type="bibr" rid="pone.0167112.ref009">9</xref>,<xref ref-type="bibr" rid="pone.0167112.ref017">17</xref>] mortalities at 30 and 90 days for ASP as compared to cephalosporin. Two studies identified cefuroxime treatment as an independent parameter for higher 30- and 90-days mortality as compared to penicillin for PS-SAB or dicloxacillin for MS-SAB [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>,<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>]. Furthermore, empirical onset of cloxacillin or cefazolin, as compared to cefuroxime, ceftriaxone or cefotaxime were associated to a significantly lower 30-days mortality in one report [<xref ref-type="bibr" rid="pone.0167112.ref007">7</xref>]. In contrast, similar clinical cure rates for oxacillin and cefazolin have been reported [<xref ref-type="bibr" rid="pone.0167112.ref017">17</xref>]. A recent meta-analysis found no significant difference in 30 or 90 days outcome for ASP versus cephalosporin therapy in MS-SAB [<xref ref-type="bibr" rid="pone.0167112.ref012">12</xref>].</p>
<p>The comparison of results in the studies mentioned above is challenging due to variations in clinical settings. Previous studies include a wide range of different ASP agents i.e. dicloxacillin [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>,<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>], cloxacillin [<xref ref-type="bibr" rid="pone.0167112.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0167112.ref017">17</xref>], nafcillin [<xref ref-type="bibr" rid="pone.0167112.ref009">9</xref>] and cephalosporin from different generations i.e. cefazolin [<xref ref-type="bibr" rid="pone.0167112.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0167112.ref009">9</xref>,<xref ref-type="bibr" rid="pone.0167112.ref017">17</xref>], cefuroxime [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>,<xref ref-type="bibr" rid="pone.0167112.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>] or ceftriaxone [<xref ref-type="bibr" rid="pone.0167112.ref007">7</xref>]. The present study applied the ASP agent cloxacillin which was used in only two earlier report [<xref ref-type="bibr" rid="pone.0167112.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0167112.ref017">17</xref>]. As with the present study, many previous reports have altered empiric antimicrobial treatment into directed treatment within 3 days of blood culture collection [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>,<xref ref-type="bibr" rid="pone.0167112.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>]. However, durations of directed antimicrobial treatment in earlier reports differ with some authors reporting median treatment durations of 15–17 days [<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>,<xref ref-type="bibr" rid="pone.0167112.ref009">9</xref>]. The present study regarded length of antibiotic therapy as proper when administered intravenously for at least 28 days for a deep infection focus and 14 days in the absence of any deep infection.</p>
<p>Previous studies on the impact of ASP and cephalosporin in SAB do not include or do not comment on the presence of any infectious disease specialist consultation [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>,<xref ref-type="bibr" rid="pone.0167112.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>,<xref ref-type="bibr" rid="pone.0167112.ref009">9</xref>,<xref ref-type="bibr" rid="pone.0167112.ref012">12</xref>,<xref ref-type="bibr" rid="pone.0167112.ref017">17</xref>] whereas in the present study altogether 88% received formal bedside infectious disease specialist consultation. Moreover, previous studies have not evaluated the potential positive prognostic impact of adjunctive rifampicin treatment whereas in the present study 61% of patients were provided with rifampicin treatment [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>,<xref ref-type="bibr" rid="pone.0167112.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>,<xref ref-type="bibr" rid="pone.0167112.ref009">9</xref>,<xref ref-type="bibr" rid="pone.0167112.ref012">12</xref>,<xref ref-type="bibr" rid="pone.0167112.ref017">17</xref>]. Previous studies have reported occurrence of secondary metastatic (deep) infection foci in 11%-21% of patients [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>,<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>,<xref ref-type="bibr" rid="pone.0167112.ref017">17</xref>] with pneumonia in 7%-17% and endocarditis in 6%-10% [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>,<xref ref-type="bibr" rid="pone.0167112.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>,<xref ref-type="bibr" rid="pone.0167112.ref017">17</xref>] of patients. In the present study 77% of patients were diagnosed with a deep infection focus including 16% endocarditis and 38% pneumonia and most deep foci were diagnosed within 3 days of positive blood cultures [<xref ref-type="bibr" rid="pone.0167112.ref004">4</xref>]. Infectious disease specialist consultations, meticulous deep infection foci localization and adjunctive rifampicin treatment have previously been associated to enhanced SAB prognosis [<xref ref-type="bibr" rid="pone.0167112.ref002">2</xref>,<xref ref-type="bibr" rid="pone.0167112.ref003">3</xref>,<xref ref-type="bibr" rid="pone.0167112.ref004">4</xref>,<xref ref-type="bibr" rid="pone.0167112.ref005">5</xref>,<xref ref-type="bibr" rid="pone.0167112.ref014">14</xref>]. However, several of the parameters with prognostic impact in the present study have been reported earlier i.e. age, underlying conditions, intensive care unit treatment, diagnosis of endocarditis and pneumonia [<xref ref-type="bibr" rid="pone.0167112.ref002">2</xref>–<xref ref-type="bibr" rid="pone.0167112.ref005">5</xref>,<xref ref-type="bibr" rid="pone.0167112.ref007">7</xref>–<xref ref-type="bibr" rid="pone.0167112.ref009">9</xref>], infectious disease specialist consultation [<xref ref-type="bibr" rid="pone.0167112.ref002">2</xref>,<xref ref-type="bibr" rid="pone.0167112.ref003">3</xref>,<xref ref-type="bibr" rid="pone.0167112.ref005">5</xref>] and adjunctive rifampicin therapy [<xref ref-type="bibr" rid="pone.0167112.ref014">14</xref>].</p>
<p>The results of the present study diverge from reports stating that ASP, as compared to cephalosporin, associates to significantly lower mortality rates [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>–<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>] and studies presenting cefuroxime as an independent parameter for 30 or 90 days mortality [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>,<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>]. Altogether, previous studies on ASP and cephalosporin in MS-SAB report overall mortality rates of 10–37% at 30-days [<xref ref-type="bibr" rid="pone.0167112.ref006">6</xref>–<xref ref-type="bibr" rid="pone.0167112.ref009">9</xref>] and 27–49% at 90-days [<xref ref-type="bibr" rid="pone.0167112.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0167112.ref008">8</xref>,<xref ref-type="bibr" rid="pone.0167112.ref017">17</xref>]. These mortality figures are considerable higher than those of the present study with 12% at 28 days and 18% at 90 days. The lower mortality in this study may have two explanations. First, we might have missed some of the more severe cases. Second, more importantly, factors such as non-delayed onset of an intravenous antibiotic treatment effective in vitro against the <italic>S</italic>. <italic>aureus</italic> blood isolate provided to each patient from the day of positive blood culture, proper duration of antibiotic therapy, infectious disease specialist consultation guided SAB management, meticulous deep infection foci localization and adjunctive rifampicin therapy have contributed to lower mortality rates. These prognostic factors have previously have been linked to favorable SAB outcomes [<xref ref-type="bibr" rid="pone.0167112.ref002">2</xref>,<xref ref-type="bibr" rid="pone.0167112.ref003">3</xref>,<xref ref-type="bibr" rid="pone.0167112.ref004">4</xref>,<xref ref-type="bibr" rid="pone.0167112.ref005">5</xref>,<xref ref-type="bibr" rid="pone.0167112.ref014">14</xref>].</p>
<p>There are weaknesses in the present study which have to be accounted for when interpreting results.</p>
<p>First, the cephalosporin group included both second (cefuroxime) and third (ceftriaxone) generation cephalosporin. Analyses with combination of antibiotic regimens from different cephalosporin generations may be viewed as controversial. However, in the Finnish healthcare system cefuroxime and ceftriaxone are commonly applied empiric antibiotics among infectious diseases. This motivates the analyzing of these two together. However, to further investigate the stability of the results, the main analyses with propensity-score adjusted Cox proportional regression analysis were re-performed by excluding ceftriaxone and comparing only first week treatment with ASP versus cefuroxime. The results of this closely resembled the main results with no significant prognostic difference at 28- or 90-days between the ASP and cefuroxime treatment.</p>
<p>Second, the patient cohort came from two separate time-periods. The two different time-periods were viewed as mandatory in order to be able to account for any changes in personnel or clinical treatment practices. However, two time-periods may raise the question whether changes in clinical practice have favored one or the other treatment group. To further analysis this, the propensity-score adjusted Cox proportional regression analysis was performed separately for the larger patient subgroup from the earlier time-period and the results demonstrated no significant prognostic difference at 28- or 90-days between the ASP and cefuroxime treatment.</p>
<p>Third, retrospective studies may be biased by differences in the patient groups such as age and underlying conditions. Moreover, it is well known that severely ill patients, as compared to patients with a more optimistic clinical condition, are more likely to receive broader spectrum antimicrobial therapy. This ´´<italic>confounding by indication”</italic> may further bias retrospective cohort analyses [<xref ref-type="bibr" rid="pone.0167112.ref018">18</xref>]. However, potential bias may be reduced through propensity-score adjusted analyses and through categorization of data according to various parameters [<xref ref-type="bibr" rid="pone.0167112.ref019">19</xref>]. In the present study patients receiving ASP had significantly less severe underlying conditions according to McCabe´s classification. Further, although statistically not significant, there were minor differences with respect to gender, age, bacteremia acquisition and need for intensive care unit treatment i.e. factors that may have influenced the final results. Moreover, the difference in patient number between ASP (n = 488) and cephalosporin (n = 92) may give suspicion that confounders of prognostic importance might have gone unaccounted for. However, the main observations were achieved by propensity-score adjusted analysis, correcting for potential differences between the ASP and cephalosporin group. Moreover, sub-analyses with categorization according to age and underlying conditions produced results that closely resembled the main observations. This indicates that the main results are robust and makes the risk for statistical bias low.</p>
<p>Fourth, with respect to the earlier time-period, the question of whether the data in the present study is valid to current clinical practice may be raised. However, although the management of SAB is continuously developed as new clinical research is published, there are fundamental elements of SAB management that has remained unchanged over the years such as prompt onset and correct duration of antibiotic treatment and meticulous identification and eradication of deep infection foci [<xref ref-type="bibr" rid="pone.0167112.ref001">1</xref>]. Infectious disease specialist consultation is known to ensure highly optimized SAB management [<xref ref-type="bibr" rid="pone.0167112.ref002">2</xref>,<xref ref-type="bibr" rid="pone.0167112.ref005">5</xref>]. The authors view that the high presence (88%) of formal bedside infectious disease specialist consultation in the present study has both ensured recording of relevant clinical patient information and guaranteed high standard clinical management of SAB. Hence, the patient data of the present study is not outdated for current clinical practice.</p>
<p>In conclusion, we observed a comparable effectiveness with respect to 28- and 90-days outcome for first week treatment with ASP versus cephalosporin in MS-SAB. The results indicate that the difference in prognostic impact between first week ASP and cephalosporin may be non-significant in patient cohorts with SAB management optimized by infectious disease specialist consultation.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0167112.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Thwaites</surname> <given-names>GE</given-names></name>, <name name-style="western"><surname>Edgeworth</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Gkrania-Klotsas</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Kirby</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tilley</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Török</surname> <given-names>ME</given-names></name>, <etal>et al</etal>. <article-title>Clinical management of Staphylococcus aureus bacteraemia</article-title>. <source>Lancet Infect Dis</source> <year>2011</year>; <volume>11</volume>:<fpage>208</fpage>–<lpage>22</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1473-3099(10)70285-1" xlink:type="simple">10.1016/S1473-3099(10)70285-1</ext-link></comment> <object-id pub-id-type="pmid">21371655</object-id></mixed-citation></ref>
<ref id="pone.0167112.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rieg</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Peyerl-Hoffmann</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>de With</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Theilacker</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Wagner</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Hübner</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Mortality of S. aureus bacteremia and infectious diseases specialist consultation—a study of 521 patients in Germany</article-title>. <source>J Infect</source> <year>2009</year>; <volume>59</volume>:<fpage>232</fpage>–<lpage>39</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jinf.2009.07.015" xlink:type="simple">10.1016/j.jinf.2009.07.015</ext-link></comment> <object-id pub-id-type="pmid">19654021</object-id></mixed-citation></ref>
<ref id="pone.0167112.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kaech</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Elzi</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Sendi</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Frei</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Laifer</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Bassetti</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Course and outcome of Staphylococcus aureus bacteraemia: a retrospective analysis of 308 episodes in a Swiss tertiary-care centre</article-title>. <source>Clin Microbiol Infect</source> <year>2006</year>; <volume>12</volume>:<fpage>345</fpage>–<lpage>52</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1469-0691.2005.01359.x" xlink:type="simple">10.1111/j.1469-0691.2005.01359.x</ext-link></comment> <object-id pub-id-type="pmid">16524411</object-id></mixed-citation></ref>
<ref id="pone.0167112.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Forsblom</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Ruotsalainen</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Mölkänen</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Ollgren</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Lyytikäinen</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Järvinen</surname> <given-names>A</given-names></name>. <article-title>Predisposing factors, disease progression and outcome in 430 prospectively followed patients of healthcare- and communityassociated Staphylococcus aureus bacteraemia</article-title>. <source>J Hosp Infect</source> <year>2011</year>; <volume>78</volume>:<fpage>102</fpage>–<lpage>07</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jhin.2011.03.010" xlink:type="simple">10.1016/j.jhin.2011.03.010</ext-link></comment> <object-id pub-id-type="pmid">21511366</object-id></mixed-citation></ref>
<ref id="pone.0167112.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Forsblom</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Ruotsalainen</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Ollgren</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Järvinen</surname> <given-names>A</given-names></name>. <article-title>Telephone Consultation Cannot Replace Bedside Infectious Disease Consultation in the Management of Staphylococcus aureus Bacteraemia</article-title>. <source>Clin Infect Dis</source> <year>2012</year>; <volume>56</volume>:<fpage>527</fpage>–<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cid/cis889" xlink:type="simple">10.1093/cid/cis889</ext-link></comment> <object-id pub-id-type="pmid">23087397</object-id></mixed-citation></ref>
<ref id="pone.0167112.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nissen</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Skov</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Knudsen</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Ostergaard</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Schønheyder</surname> <given-names>HC</given-names></name>, <name name-style="western"><surname>Frimodt-Møller</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Effectiveness of penicillin, dicloxacillin and cefuroxime for penicillin-susceptible Staphylococcus aureus bacteraemia: a retrospective, propensity-score-adjusted case–control and cohort analysis</article-title>. <source>J Antimicrob Chemother</source> <year>2013</year>; <volume>68</volume>:<fpage>1894</fpage>–<lpage>90</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jac/dkt108" xlink:type="simple">10.1093/jac/dkt108</ext-link></comment> <object-id pub-id-type="pmid">23599360</object-id></mixed-citation></ref>
<ref id="pone.0167112.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Paul</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Zemer-Wassercug</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Talker</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Lishtzinsky</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Lev</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Samra</surname> <given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Are all b-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?</article-title> <source>Clin Microbiol Infect</source> <year>2011</year>; <volume>17</volume>:<fpage>1581</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1469-0691.2010.03425.x" xlink:type="simple">10.1111/j.1469-0691.2010.03425.x</ext-link></comment> <object-id pub-id-type="pmid">21073629</object-id></mixed-citation></ref>
<ref id="pone.0167112.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rasmussen</surname> <given-names>JB</given-names></name>, <name name-style="western"><surname>Knudsen</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Arpi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Schønheyder</surname> <given-names>HC</given-names></name>, <name name-style="western"><surname>Benfield</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Ostergaard</surname> <given-names>C</given-names></name>. <article-title>Relative efficacy of cefuroxime versus dicloxacillin as definitive antimicro-bial therapy in methicillin-susceptible Staphylococcus aureus bacteraemia: apropensity-score adjusted retrospective cohort study</article-title>. <source>J Antimicrob Chemother</source> <year>2013</year>; <volume>69</volume>:<fpage>506</fpage>–<lpage>14</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jac/dkt375" xlink:type="simple">10.1093/jac/dkt375</ext-link></comment> <object-id pub-id-type="pmid">24078468</object-id></mixed-citation></ref>
<ref id="pone.0167112.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Choe</surname> <given-names>PG</given-names></name>, <name name-style="western"><surname>Song</surname> <given-names>KH</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>SW</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>HB</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>NJ</given-names></name>, <etal>et al</etal>. <article-title>Is cefazolin infe-rior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureusbacteremia?</article-title> <source>Antimicrob Agents Chemother</source> <year>2011</year>; <volume>55</volume>:<fpage>5122</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.00485-11" xlink:type="simple">10.1128/AAC.00485-11</ext-link></comment> <object-id pub-id-type="pmid">21825299</object-id></mixed-citation></ref>
<ref id="pone.0167112.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nannini</surname> <given-names>EC</given-names></name>, <name name-style="western"><surname>Singh</surname> <given-names>KV</given-names></name>, <name name-style="western"><surname>Arias</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Murray</surname> <given-names>BE</given-names></name>. <article-title>In vivo effect of cefa-zolin, daptomycin, and nafcillin in experimental endocarditis with amethicillin-susceptible Staphylococcus aureus strain showing an inoculumeffect against cefazolin</article-title>. <source>Antimicrob Agents Chemother</source> <year>2013</year>; <volume>57</volume>: <fpage>4276</fpage>–<lpage>81</lpage>.</mixed-citation></ref>
<ref id="pone.0167112.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nannini</surname> <given-names>EC</given-names></name>, <name name-style="western"><surname>Stryjewski</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Singh</surname> <given-names>KV</given-names></name>, <name name-style="western"><surname>Bourgogne</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Rude</surname> <given-names>TH</given-names></name>, <name name-style="western"><surname>Corey</surname> <given-names>GR</given-names></name>, <etal>et al</etal>. <article-title>Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolintreatment failure</article-title>. <source>Antimicrob Agents Chemother</source> <year>2009</year>; <volume>53</volume>:<fpage>3437</fpage>–<lpage>41</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.00317-09" xlink:type="simple">10.1128/AAC.00317-09</ext-link></comment> <object-id pub-id-type="pmid">19487449</object-id></mixed-citation></ref>
<ref id="pone.0167112.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vardakas</surname> <given-names>KZ</given-names></name>, <name name-style="western"><surname>Apiranthiti</surname> <given-names>KN</given-names></name>, <name name-style="western"><surname>Falagas</surname> <given-names>ME</given-names></name>. <article-title>Antistaphylococcal penicillins versus cephalosporins for definitive treatment of meticillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis</article-title>. <source>Int J Antimicrob Agents</source> <year>2014</year>; <volume>44</volume>:<fpage>486</fpage>–<lpage>92</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ijantimicag.2014.09.002" xlink:type="simple">10.1016/j.ijantimicag.2014.09.002</ext-link></comment> <object-id pub-id-type="pmid">25311850</object-id></mixed-citation></ref>
<ref id="pone.0167112.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ruotsalainen</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Järvinen</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Koivula</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Kauma</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Rintala</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Lumio</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Finlevo Study Group: Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients</article-title>. <source>J Intern Med</source> <year>2006</year>; <volume>259</volume>:<fpage>179</fpage>–<lpage>90</lpage>.</mixed-citation></ref>
<ref id="pone.0167112.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Forsblom</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Ruotsalainen</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Järvinen</surname> <given-names>A</given-names></name>. <article-title>Improved outcome with early rifampicin combination treatment in methicillin-sensitive Staphylococcus aureus bacteraemia with a deep infection focus—a retrospective cohort study</article-title>. <source>PLoS One</source> <year>2015</year>; <volume>13</volume>:<issue>10</issue>:<fpage>e0122824</fpage>.</mixed-citation></ref>
<ref id="pone.0167112.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McCabe</surname> <given-names>WR</given-names></name>, <name name-style="western"><surname>Jackson</surname> <given-names>GG</given-names></name>. <article-title>Gram negative bacteraemia. Etiology and ecology</article-title>. <source>Arch Intern Med</source> <year>1962</year>; <volume>110</volume>:<fpage>847</fpage>–<lpage>55</lpage>.</mixed-citation></ref>
<ref id="pone.0167112.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Levy</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Fink</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Marshall</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Abraham</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Angus</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Cook</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>SCCM/ESICM/ ACCP/ATS/SIS: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference</article-title>. <source>Crit Care Med</source> <year>2003</year>; <volume>31</volume>:<fpage>1250</fpage>–<lpage>56</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/01.CCM.0000050454.01978.3B" xlink:type="simple">10.1097/01.CCM.0000050454.01978.3B</ext-link></comment> <object-id pub-id-type="pmid">12682500</object-id></mixed-citation></ref>
<ref id="pone.0167112.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bai</surname> <given-names>AD</given-names></name>, <name name-style="western"><surname>Showler</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Burry</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Steinberg</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Ricciuto</surname> <given-names>DR</given-names></name>, <name name-style="western"><surname>Fernandes</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study</article-title>. <source>J Antimicrob Chemother</source> <year>2015</year>; <volume>70</volume>:<fpage>1539</fpage>–<lpage>46</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jac/dku560" xlink:type="simple">10.1093/jac/dku560</ext-link></comment> <object-id pub-id-type="pmid">25614044</object-id></mixed-citation></ref>
<ref id="pone.0167112.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Psaty</surname> <given-names>BM</given-names></name>, <name name-style="western"><surname>Koepsell</surname> <given-names>TD</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Weiss</surname> <given-names>NS</given-names></name>, <name name-style="western"><surname>Siscovick</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Rosendaal</surname> <given-names>FR</given-names></name>, <etal>et al</etal>. <article-title>Assessment and control for confounding by indication in observational studies</article-title>. <source>J Am Geriatr Soc</source> <year>1999</year>; <volume>47</volume>:<fpage>749</fpage>–<lpage>54</lpage>. <object-id pub-id-type="pmid">10366179</object-id></mixed-citation></ref>
<ref id="pone.0167112.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rosenbaum</surname> <given-names>PR</given-names></name>, <name name-style="western"><surname>Rubin</surname> <given-names>DB</given-names></name>. <article-title>The central role of the propensity score inobservational studies for causal effects</article-title>. <source>Biometrika</source> <year>1983</year>; <volume>70</volume>:<fpage>41</fpage>–<lpage>55</lpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>